A detailed history of Central Trust CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Central Trust CO holds 23 shares of BPMC stock, worth $2,107. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23
Previous 23 -0.0%
Holding current value
$2,107
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 26, 2023

BUY
$46.9 - $66.0 $1,078 - $1,518
23 New
23 $1,000
Q1 2022

May 03, 2022

SELL
$54.1 - $110.08 $7,790 - $15,851
-144 Reduced 96.0%
6 $0
Q2 2021

Jul 23, 2021

BUY
$82.78 - $101.0 $8,278 - $10,100
100 Added 200.0%
150 $13,000
Q1 2021

Apr 23, 2021

BUY
$90.71 - $108.28 $1,814 - $2,165
20 Added 66.67%
50 $4,000
Q4 2020

Jan 29, 2021

SELL
$92.08 - $124.48 $1,841 - $2,489
-20 Reduced 40.0%
30 $3,000
Q2 2020

Jul 14, 2020

BUY
$57.09 - $79.27 $2,854 - $3,963
50 New
50 $3,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.47B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Central Trust CO Portfolio

Follow Central Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Central Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Central Trust CO with notifications on news.